mage AF/16/7

EXPEDITED PROCESSING RESPONSE UNDER 37 C.F.R. § 1.116 OROUP ART UNIT 1617

Docket No. 44657-AAA-PCT-US/JPW/GJG

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :

Joseph R. Berger

Serial No.:

10/052,961

Examiner: R. Travers

Filed

January 18, 2002

Art Unit: 1617

For

METHOD

AMELIORATING

MUSCLE

WEAKNESS/WASTING IN A PATIENT INFECTED WITH

HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1

FOR

1185 Avenue of the Americas New York, New York 10036 March 5, 2004

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## AMENDMENT UNDER 37 C.F.R. § 1.116 IN RESPONSE TO JANUARY 14, 2004 OFFICE ACTION, AND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Amendment is submitted in response to the January 14, 2004 Final Office Action issued by the U.S. Patent and Trademark Office in connection with the above-identified application. A response to the January 14, 2004 Final Office Action is due April 14, 2004 and this Amendment is being timely filed.

By this Amendment applicant has merely updated in the subject specification the cross-reference to parent application U.S. Serial No. 09/469,817 to reflect that it has issued on December 30, 2003 as U.S. Patent No. 6,670,351. Accordingly, this Amendment should be entered under 37 C.F.R. § 1.116.

Please amend the subject application as follows: